Amarin Corporation plc
AMRNHealthcare|Drug Manufacturers - General|IE
$11.61
+0.04 (+0.30%)
Tangible Book / Share
$20.79
Cash / Share
$15.53
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03428477 EPA for Metastasis Trial 2 | Liver Metastasis, Colon Cancer | P3 | Active | 418 | RCT, Double-blind | Icosapent Ethyl |
| NCT06637657 Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD | Acute Coronary Syndrome | Recruiting | 5,586 | — | — | |
| NCT04505098 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults | Covid19, Atherosclerosis | P4 | Terminated | 39,600 | RCT, Single-blind | Icosapent ethyl |
| NCT00146211 TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease | Huntington Disease | P3 | Completed | 300 | RCT, Double-blind | Ethyl-EPA (Miraxion™) |
| NCT01047683 Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL | Hypertriglyceridemia | P3 | Completed | 229 | RCT, Double-blind | AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo |
| NCT01047501 Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) | Hypertriglyceridemia | P3 | Completed | 702 | RCT, Double-blind | AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo |
| NCT04460651 PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial | COVID19 | P3 | Completed | 4,093 | RCT, Double-blind | Icosapent ethyl (IPE), Placebo |
| NCT01492361 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin | Cardiovascular Diseases | P3 | Completed | 8,179 | RCT, Double-blind | AMR101, Placebo, Statin therapy |
| NCT04412018 An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 | COVID-19, Inflammatory Response | P2 | Completed | 100 | RCT, Open-label | Icosapent ethyl |
| NCT03885661 Vascepa to Accelerate Lipoprotein Uptake and Elimination | Lipid Disorder, Triglycerides High | P1 | Completed | 20 | RCT, Double-blind | Icosapent Ethyl 1000 MG [Vascepa] |
| NCT07769359 Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjects | Bioequivalence, Adhesion | P1 | Completed | 35 | RCT, Open-label | — |